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Abstract 
BACKGROUND: BDNF implies to the development of abnormal nerves and neurotransmission that occurred 
during the changes of cognitive functions. However, in determining initial diagnosis of schizophrenia, 
measurements focus on the presences of positive and negative symptoms, and general psychopathological 
features without concerning the BDNF serum, which involves in central nervous system as the main symptom of 
schizophrenia. 
AIM: To determine the relation of BDNF serum level to cognitive functions of schizophrenia patients based on 
sub-domain of Montreal Cognitive Assessment Indonesia Version (MoCA-Ina) 
METHODS: This study was carried out based on observational analysis with cross-sectional design study. The 
samples were collected by non-probability sampling and consecutive sampling by recruiting 65 of male 
schizophrenia patients at Prof. Dr. M. Ildrem Mental Hospital, Medan, North Sumatera, Indonesia. BDNF serum 
levels were analysed throughout quantitative sandwich enzyme immunoassay method, while the cognitive 
functions were conducted by performing the MoCA-Ina, which concern to attentions and concentrations, executive 
function, memory, languages, visuoconstructional abilities, numerical calculation, and orientation. 
RESULTS: The serum level of BDNF was accounted averagely for 27161.26, with 5350.37 of standard deviation. 
There was positive correlation with medium strength (r = 0.4 - < 0.6) in visuospatial function, attention (r = 0.437), 
and memory (r = 0.413). 
CONCLUSION: Relation between BDNF serum level and cognitive function occurred in visuospatial, attention 
and memory domains based on MoCA-Ina assessment. 
 
 
 
 
 
Introduction 
 
Cognitive impairment is experienced by 
almost 70% of schizophrenia patients, while the rest 
of that number is classified as schizophrenia patients 
with neuropsychopathologically normal. This event 
shows significantly that cognitive dysfunction in 
schizophrenia patients is a normal condition. The 
dysfunctional of cognition is detected before the 
diagnosis of schizophrenia in which every cognitive 
domain is influenced particularly in memory, attention, 
motoric abilities, executive function, and intelligence. 
This dysfunction is also affected the social function 
and functional results [1] of the individuals which 
cognitive disabilities and functional disturbance are 
commonly found in schizophrenia individuals. It has 
been reported that the treatment of cognitive abilities 
had the potential in altering, and positive correlation of 
BDNF serum level to the functional abilities of 
schizophrenia patients, particularly in their memory 
[4], [5]. However, a few studies have been carried out 
merely in investigating the relation of BDNF to 
cognitive function, specifically to basic learning 
abilities including image projections, reading, writing, 
calculating, verbal memory, and visual perception. 
The knowledge about learning function of 
schizophrenia patients as well as its relation to 
cognitive functions and impairments is important to be 
understood due to the possibilities in mapping the 
academic competence of patients and effective 
intervention plan. 
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Studies that have been carried out in the 
recent two decades provide the relation of cognitive 
performance and neurotrophin system. This system is 
one part of systems that play important role in the 
growth factor of polypeptide, which involves to the 
brain development, differentiation and life expectancy 
of neurons, synaptic plasticity and connectivity. The 
neurotropic group consists of nerve growth factor 
(NGF), which is originated from the derivation of brain 
neutrophil factor or brain-derived neutrophil factor 
(BDNF), neurotrophin-3 (NT-3), neurotropic 4/5 
(NT4/5) [3]. Many studies have reported that 
relationship between BDNF variants and cognitive 
functions such as psychomotor speed, attention and 
memory [7], poor visuospatial performance, 
decreased attention [20] occurred among 
schizophrenia patients. Other studies have also found 
that the decrease in BDNF serum levels and cognitive 
impairment in schizophrenia patients have been 
reported to be depending on the polymorphisms of 
BDNF Val66Met4, rs6265, rs73103411 associated 
with memory [7], and rs7124442 [7]. On the other 
hand, in a study conducted in 2013, psychosis 
patients were reported to have a positive relationship 
between BDNF plasma and five cognitive domains 
which were learning ability, immediate and delayed 
memory, abstract thinking and processing speed, in 
which occurred during 6 months of monitoring. This 
relation persisted after the controlling of prescribed 
medication, drug consumption, intelligence quotient 
(IQ), and negative symptoms that were appeared. 
However, in a healthy control group, the BDNF levels 
were not associated with cognitive test results [8]. 
Post-mortem studies to the tissue brain of 
schizophrenic patients have reported that the BDNF 
mRNA and protein levels showed significant changes 
within the cerebral cortex, anterior cingulated cortex, 
and hippocampus parts of the patients compared to 
those who were healthy. The same study also 
reported that the BDNF levels reduced significantly in 
schizophrenic patients although those were not in 
blood composition, and the correlation of the level 
dosages of antipsychotic clozapine occurred [9]. 
BDNF performs importantly in cognitive 
functions, which was investigated firstly in cellular and 
molecular study. It has been reported that the BDNF 
secretion is a necessity for long-term potentiation 
(LTP) and long-term depression (LTD), which 
occurred as cellular mechanisms for learning and 
memorizing. The changes of neurotropic factor such 
as BDNF and gene levels can contribute to the 
development of brain, synaptic disconnection and 
failure in neuroplasticity, and at the very least it can 
explain the half morphological and neurochemical of 
brain failures found in schizophrenic patients. For 
instance, a study conducted in 2013 has reported that 
BDNF was distributed mostly in the brain, and it was 
related to several mental disorders which implied to 
the impairment of brain and plasticity developments of 
schizophrenic patients [6]. This factor also involves in 
schizophrenic pathogenesis, and it also shows the 
deficit of pathophysiological cognitive which can be 
considered as the main symptom of schizophrenia. 
Based on the previous explanations, literature review 
has shown no studies that have been carried out in 
Indonesia, particularly for schizophrenic patients from 
Medan to provide clinical information to both 
practitioners and psychiatrists about the relation of 
cognitive domains to the BDNF serums level of 
schizophrenia patients assessed from MoCA-Ina. 
 
 
Research Methodologies 
 
Participants 
Research samples in this study included 65 
people with schizophrenic disorder. All subjects based 
on inclusion and exclusion criteria were inquired for 
the permission throughout informed consent in 
following this study. After receiving the permission, the 
recruited inclusion samples were male schizophrenic 
patients which were diagnosed based on Indonesian 
Guidelines of Classification and Diagnosis and Mental 
Health Disorders III (PPDGJ III) within ages in 
between 20 to 60 years old. According to the first step 
in determining the diagnosis, structured interviewed 
based on Mini International Statistical Classification of 
Diseases-10 (Mini ICD-10). To determine the 
cognitive functions of the participants, Indonesian 
version of MoCA measurements which have been 
validated based on transcultural characteristics were 
performed [12]. 
Whilst, the inclusion participants were 
schizophrenic patients who have been experiencing 
this disorder for over two years of stable phase of 
medication. This phase is in remission stages which 
aim to prevent relapse and to support the increase of 
cognitive functions. The measurements of PANSS to 
the research subjects aim to assess the clinical 
symptoms of schizophrenia, therefore, samples were 
those who had PANSS score ≤ 60, have the ability in 
understanding Bahasa Indonesia (Indonesia 
language), willing to be interviewed and respondents, 
the lasted educations were junior high or equivalent to 
senior high, and tertiary educations. Meanwhile, the 
exclusion criteria in this study were patients who have 
been suffering from other health disorders with a 
history of alcohol use. 
 
The Measurements of BDNF Serum 
Subjects were gathered for the blood samples 
collection. As many as 5 ml of blood samples were 
carried out 12 hours before taking medications by 
laboratory medical officers until the required samples. 
The samples were tested and measured in order to 
obtain the results of BDNF serum level [10]. The 
serum levels of BDNF were analysed by performing 
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the quantitative sandwich enzyme immunoassay. The 
BDNF levels collected in this analysis were plasma 
and normal blood clots ranged between 6.186 – 
42.580 pg/ ml [11]. Then, 5 cc of bloods were placed 
into the STT tube to be shaken for obtaining the 
homogenous features. Afterward, the blood samples 
were allowed to stand for 30-40 minute, and they were 
immediately placed into centrifuge with a speed of 
3000 rpm for 15 minutes. As a result, the separated 
samples were obtained, for the serum itself was 
placed into three sample cups with 0.5 cc. These each 
three samples based on the participants were stored 
at 20
o
C to be measured for the value of BDNF serum 
levels in the blood. 
 
MoCA-Ina Assessment 
The Montreal Cognitive Assessment of 
Indonesian Version (MoCA-Ina) measurements were 
performed to determine the cognitive functions of 
subjects. Sub-domains of MoCA-Ina tests were 
designed as a quick-screening instrument to evaluate 
light cognitive dysfunctions. Total score of this 
assessment is 30 points, while ≥ 26 is classified 
normal [13]. MoCA-Ina assessments are consisted by: 
1. Visuospatial, it was assessed by a clock drawing 
task and three-dimensional of boxes; 2. Executive 
function, it was assessed by trial making B task, 
phonemic ability task, and abstract words; 3. 
Language, it was measured by asking the participant 
to mentioned three unfamiliar animal pictures which 
were elephant-rhinoceroses and camels, repeating 
two difficult sentences, and fluently pronounced two 
sentences; 4. Attention/awareness, it was measured 
by giving the continuously attentions based on the 
knocking detection; 5. Concentration, it was assessed 
by performing the serial reduction task; 6. Working 
memory, it was performed by asking the subjects to 
mention digit numbers forwardly and backwardly; 7. 
Memory, it was performed by giving short-term 
memory recall task and delayed recall task; and 8. 
Orientation, it was measured throughout place and 
time. 
 
Statistical Analysis 
This study is observational analytical study 
with cross-sectional approach. The normality 
validation was performed by using Kolmogorov-
Smirnov test due to the sample numbers which were 
more than 50. Then, the data was analysed to obtain 
the correlation value by performing the SPSS 
analysis. 
Results 
 
Demographic data of Subjects 
The demographical description of 
schizophrenic patients is displayed in Table 1. The 
variables with categorical scales are shown in 
frequency and proportion including the average and 
standard of deviation. According to the Table 1, the 
proportions of the ages were 13.8% for 20-30 years of 
age, 53.8% for 31-40 years of age, 26.2% for 41-50 
years of age, and 6.2% for 51-60 years of age. The 
highest population is those who were 31-40 years of 
age. Meanwhile, the highest percentage for the last 
educational background was the senior high school 
which accounted for 72.3%. More than a half of the 
schizophrenic patients that were recruited within the 
inclusion criteria were married, and based on the 
duration of experiencing the schizophrenic disorders 
were 2-5 years for 52.3%, and 47.7% for over 5 years. 
The smoking characteristics of the schizophrenic 
patients were found to be smoking for 41.5% and non-
smoking individuals for 58.8%. 
Table 1: The Distribution of Participants Based on 
Demographical Characteristics 
Variables n (individuals) Percentage (%) 
Age   
20-30 YoA
*
 9 13.8 
31-40 YoA
*
 35 53.8 
41-50 YoA
*
 17 26.2 
51-60 YoA
*
 4 6.2 
Education   
Junior High 15 4.6 
Senior High 47 72.3 
Tertiary Education 3 4.6 
Marital Status   
Not-Married 28 43.1 
Married 37 56.9 
Duration of Illness   
2-5 Years 34 52.3 
> 5 Years 31 47.7 
Smoking Characteristics   
Smoker 27 41.5 
Non-Smoker 38 58.8 
 
Serum Levels of BDNF of the 
 Schizophrenic Participants 
The following Table 2 shows the serum level 
of BDNF with average level of 27161.26 ± 5350.37. 
Based on the normality validation of the data by using 
the Kolmogorov-Smirnov test, it was obtained that the 
p is 0.20 (p > 0.05). Therefore, it can be stated that 
the data was in normal distribution. 
Table 2: The Average Serum Levels of BDNF of Schizophrenia 
Participants 
Variabel Rerata SD p 
BDNF 27161.26 5350.37 0.20 
 
The Correlation of BDNF Serum Levels to 
 Six Domains Function 
The following Table 3 below highlights the 
correlation results between BDNF serum levels to 
cognitive domains of schizophrenic subjects. 
According to the table, it can be seen that the 
Spearman’s correlation of the BDNF serum levels had 
the p value in between 0.3-0.35 in executive functions, 
language and working memory, while on the 
concentration and orientation domains, both of them 
had the correlation value over 0.5. In the meantime, 
the visuospatial, attention and memory domains 
accounted for 0.001 of p value. 
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Table 3: Spearman's Correlation Values of Domain Functions 
Domain ẋ BDNF Score r p 
Visuospatial 2.85 ± 0.83 27161.26 ± 5350.37 0.402 0.001 
Executive Functions 2.11 ± 0.75 27161.26 ± 5350.37 -0.132 0.296 
Language 4.54 ± 0.83 27161.26 ± 5350.37 -0.120 0.342 
Attention 0.62 ± 0.49 27161.26 ± 5350.37 0.437 0.00 
Concentration 1.94 ± 0.91 27161.26 ± 5350.37 0.081 0.522 
Domain Memori Kerja 1.88 ± 0.33 27161.26 ± 5350.37 -0.124 0.327 
Memory 2.32 ± 0.92 27161.26 ± 5350.37 0.413 0.001 
Orientation 5.28 ± 0.65 27161.26 ± 5350.37 0.075 0.550 
 
The correlation among domain samples can 
be determined based on Table 3. On the visuospatial 
domain, there was positive correlation to the serum 
level with medium power (r = 0.4 - < 0.6) [14], and the 
same feature occurred to the attention and memory 
domains. For the orientation, working memory, 
concentration, language and executive functions, no 
correlations occurred due to the p value over 0.05. 
 
 
Discussion 
 
This study is the first study carried out in 
Indonesia, particularly in Medan, North Sumatera. The 
aims were to investigate the correlation between the 
BDNF serum levels to the cognitive functions of 
schizophrenic patients assessed by the MoCA-Ina. 
 
The Correlation of Demographical Studies 
 and BDNF Serum 
The demographical characteristics have 
reported that the ages were classified into 20-30, 31-
40, 41-50, and 51-60 years of old. Based on the 
results, the highest percentage of schizophrenic 
patients was found in 31-40 years of old, accounted 
for over a half, and it was followed by 41-50 years of 
old for just above a quarter. This implies to the initial 
schizophrenic disorder occurred in the middle of age 
of 30s. For the male patients, the highest onset ages 
for the first episode of psychotic is started in the 
middle ages of 20 years old [15]. It has been reported 
that cohort studies of unhealthy teenagers were found 
no correlation between Va166Met polymorphism to 
the memory [16], while the other study has reported 
that the a late adults ages group was observed to 
have no correlation between polymorphism in the 
normal aging period of time and the decrease of 
cognitive functions [17]. The educational 
characteristics had the highest percentage in 
secondary schools which accounted over 75%. 
According to the marital status of the subjects, it was 
found that schizophrenic disorders were found from 
those who had married contributed for 56.9%, but this 
study showed differently to a study that reported 
schizophrenic patients occurred for non-married 
status for 51%, married for 27.9%, and divorced for 
21.1% [5]. 
Based on the duration of illness in 
experiencing the schizophrenic disorders, the 
durations were 52.3 per cent for 2-5 years, and over 
five years (47.7%). The longer duration affected the 
visuo-motoric functions, and delayed visual memory, 
as it has been reported by a study which aimed to 
verify whether the duration of illness had the effect for 
cognitive impairments or another covariates 
disturbance to the neuropsychological disorders. On 
the other hand, neuropsychological disorders have 
been reported to be related to the aging, educational 
backgrounds, sexes, as well as the treatment status 
[18]. For the smoking experiences, it was found that 
41% of schizophrenic patients recruited for this study 
were smokers and the others were not smokers. 
Studies conducted in 2013 and 2012 found that 
smoking were resulted in influencing the cognitive 
functions. The act of smoking or nicotine consumption 
could have repaired several cognitive deficits for the 
schizophrenic patients as the self-medication. This 
observation showed that the dysfunction of nicotine 
acetylcholine receptor signaling might have involved 
to the etiological cognitive dysfunction to 
schizophrenia [19], [20]. Zhang et al., 2010 [21], has 
reported that there was an increase of BDNF serum 
levels to the smoking schizophrenic patients [21]. 
 
The Correlation of BDNF to the Cognitive 
 Functions 
According to the Table 2, it was found that the 
BDNF serum levels with average number of 27161.26 
± 5350.37. Zhang et al., has reported in 2016 which 
involved 657 of hospitalized schizophrenic patients 
and 445 of normal patients to determine several 
factors that might have contributed to the decrease of 
BDNF of the patients, and those included the clinical 
status of the patients, the sub-types of recruited 
schizophrenic patients, and the types, dosages as 
well as the duration of antipsychotic prescription [4]. 
On the other hand, Rowbotham et al., [22] 2015 found 
from 14 studies (910 patients and 717 of patients as a 
control group) that 8 studies have reported to have 
decreases of BDNF serum levels to the schizophrenic 
patients compared to the control; 3 studies with 274 
subjects found 128 subjects to have increased BDNF 
serum levels; the other 3 studies reported no 
differences of BDNF serum levels among the groups. 
The meta-analysis of all studies was collected to 
confirm the decreasing of BDNF levels of 
schizophrenic patients to be compared to the control 
group, however, no significant results were found in 
no medication cases. A study conducted by Djordjevi 
et al., [23] in 2016 found that the BDNF serum levels 
were significantly lower (20.38 ± 3.73 ng/mL, P = 
1.339 E-05), whereas the NO2 concentration of 
plasma was significantly higher (84.3 (72-121) 
mmol/L, P = 4.357E-08) than those who were 
classified as control healthy (25.65 ± 4.32 ng/mL; 60.9 
(50-76) mmol/ L respectively) [23]. Based on the 
assessment of cognitive function for the eight domains 
to the schizophrenic patients, it was found positive 
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correlation with medium power (r = 0.4 - < 0.6) to the 
visuospatial (r = 0.402), attention (r = 0.437), and 
memory (r = 0.413). This study implies that there was 
relation between the BDNF serum levels to the 
decrease of cognitive functions of schizophrenia 
patients. 
The lower BDNF serum levels are related to 
the smaller hippocampi and deficient recall functions. 
The BDNF serum levels as a significant factor are 
related to the hippocampi and the decreasing of 
memory recall [24]. A study carried out by Aaron has 
depicted the importance of BDNF involvement in 
cognitive process in spatial learning and memory, 
which showed the significant relations between lower 
level of pBDNF to smaller hippocampal and deficit 
recall. The BDNF acts as the acsonal authentic 
growth, and the intensification of synaptic seems to be 
mediated by the receptor which is related to BDNF, 
such as tyrosine-receptor kinase B (TrkB). The role of 
BDNF as biomarker is not completely determined by 
the current obtained data and results. For instance, 
specific toschizophrenic has not been proven yet, but 
the decreasing of BDNF level serum has also been 
reported in patients who have been experiencing 
neuro-degenerative and another neuropsychiatric 
illness. The findings related to the preservation of 
pBDNF concentration after training and learning have 
shown the roles of BDNF as the mechanism which 
may be relating to the performance during cognitive 
training [25]. A study conducted by Choon in 2011 
[26], a significant genotype effects have been found in 
verbal memory performance and BDNF (F1.436 = 
4.51, p =0.03) and the visuospatial abilities (F1.436 = 
4.12, p = 0.04). 
BDNF Met variant is related to verbal memory 
and visuospatial disturbance may have potential 
implication of medication to schizophrenic patients 
due to the main and persistent psychosocial disorders 
such as the cognitive functions of schizophrenic 
patients [26]. In a study carried out by de Azua et al., 
[8] in 2013 which involved pyschosis, has reported 
that a positive correlation between BDNF plasmas 
and five cognitive domains (including learning abilities, 
instant and delayed memory, abstract thinking and 
processing speed) after six months of observation. It 
is found that strong relation after the consumption of 
prescribed medication, drugs abuse, intelligence 
quotient (IQ), and negative symptoms, and the healthy 
control group, the BDNF level is not related to the 
cognitive function tests results. 
In conclusion, this study involved 65 of 
schizophrenic patients which were recruited from the 
Mental Hospital of Prof. dr. M. Ildrem Medan from 
March 2017 to August 2017. According the findings, 
there was medium correlation (r = 0.4 - < 0.6) 
between BDNF serum levels and cognitive functions 
which were assessed by MoCA-Ina in visuospatial 
domain, attention, and memory. This study focused on 
demographical characteristics of the participants 
without concerning the smoking lifestyles to the 
patient which have been reported by previous studies 
in 2013 and 2012 due to the influence of smoking in 
affecting the cognitive functions. Smoking or nicotine 
consumption have been reported to repair several 
cognitive deficits or it acts as self-medication. This 
observation shows that the dysfunction within the 
nicotine acetylcholine receptor signaling may have 
involved in etiological cognitive deficits in 
schizophrenia. It is expected that further clinical 
observation related to drugs and medication could 
have been designed to investigate their relationship in 
improving BDNF serum levels whether those are 
related to cognitive functions or cognitive stimulations 
of schizophrenic patients. 
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